Incidence of Squamous Cell Carcinoma and Other Skin Neoplasia in Subjects With Actinic Keratosis Treated With Ingenol Disoxate Gel 0.018% or 0.037%, or Vehicle
Phase of Trial: Phase III
Latest Information Update: 22 Jun 2018
At a glance
- Drugs Ingenol disoxate (Primary)
- Indications Actinic keratosis; Squamous cell cancer
- Focus Therapeutic Use
- Sponsors LEO Pharma
- 13 Jun 2018 Status changed from active, no longer recruiting to discontinued.
- 14 Apr 2018 This trial has been Discontinued in Germany.
- 30 Mar 2018 This trial has been Discontinued in Spain.